Literature DB >> 19413461

PecSys: in situ gelling system for optimised nasal drug delivery.

Peter Watts1, Alan Smith.   

Abstract

PecSys (PS) is a proprietary pectin-based drug delivery system designed to gel when applied to mucosal surfaces and with potential areas of application for drugs used in local and systemic disease therapy. The current area of focus is intranasal drug delivery where PS is being used to optimise absorption of lipophilic drugs into the systemic circulation. Pectin is described as GRAS (generally regarded as safe) with an excellent regulatory position through its long history of pharmaceutical and food usage. Tests to measure the functional gelling properties of pectin raw material and PS have been devised and validated. The PS-based products at the most advanced stages of development are intranasal formulations containing opioid analgesics intended to provide rapid pain relief with simple and convenient dosing and minimal side effects. The profile of such drugs may not be optimal through current routes of delivery and the ability of PS to modulate their pharmacokinetic profiles, such as attenuation of the peak plasma concentration (Cmax), has been demonstrated in clinical testing. The lead product using PS is a fentanyl nasal spray formulation (NasalFent), which has successfully met the primary objective in a pivotal Phase III clinical study and is scheduled for regulatory filings in the first half of 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19413461     DOI: 10.1517/17425240902939135

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  25 in total

1.  Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.

Authors:  Lukas Radbruch; Luis M Torres; John E Ellershaw; Antonio Gatti; Guillermo Luis Lerzo; Julia Revnic; Donald Taylor
Journal:  Support Care Cancer       Date:  2011-03-22       Impact factor: 3.603

2.  Current understanding of nasal morphology and physiology as a drug delivery target.

Authors:  Julie D Suman
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

3.  A philosophical critique of the UK's National Institute for Health and Care Excellence guideline 'Palliative care for adults: strong opioids for pain relief'.

Authors:  David Fearon; Sean Hughes; Sarah G Brearley
Journal:  Br J Pain       Date:  2018-01-10

4.  Nasal delivery of fentanyl.

Authors:  Peter Watts; Alan Smith; Michael Perelman
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

Review 5.  Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer.

Authors:  Katherine A Lyseng-Williamson
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

6.  Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin.

Authors:  Zheng Cai; Xiangrong Song; Feng Sun; Zhaoxiang Yang; Shixiang Hou; Zhongqiu Liu
Journal:  AAPS PharmSciTech       Date:  2011-08-31       Impact factor: 3.246

Review 7.  Pharmacotherapy for breakthrough cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

Review 8.  Multidimensional Treatment of Cancer Pain.

Authors:  Weiyang Christopher Liu; Zhong Xi Zheng; Kian Hian Tan; Gregory J Meredith
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

Review 9.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

Review 10.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.